Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial

Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial

BACKGROUND Intestinal mast cells may cause gastrointestinal symptoms in patients with diarrhea-dominant irritable bowel syndrome (IBS). The objective of this study was to determine the effect of mesalazine on the number of lamina propria mast cells and clinical manifestations of patients with diarr...

Full description

Bibliographic Details
Main Authors: Mohammad Reza Ghadir, Mehri Poradineh, Masoud Sotodeh, Reza Ansari, Shadi Kolahdoozan, Ahmad Hormati, Mohammad Hosein Yousefi, Samaneh Mirzaei, Homayoon Vahedi
Format: Article
Language:English
Published: Iranian Association of Gastroenterology and Hepatology, Shiraz University of Medical Sciences 2017-01-01
Series:Middle East Journal of Digestive Diseases
Subjects:
Mesalazine
IBS-D
Symptoms
Intestinal Mucosa
Mast cells
Biomarkers
Online Access:http://www.mejdd.org/index.php/mejdd/article/view/1720

Internet

http://www.mejdd.org/index.php/mejdd/article/view/1720

Similar Items